We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
17
Mar 2026
A large meta-analysis of 50 cohort studies involving over three million adults found that higher consumption of certain fermented foods is associated with lower risks of all-cause and cardiovascular mortality. Fermented milk products also showed inverse associations with cancer mortality, while other foods like miso and bread showed no consistent effects.
17
Mar 2026
Researchers engineered a two-strain microbial system that converts PET-derived terephthalic acid into levodopa, overcoming key bottlenecks in transport and enzyme inhibition. The proof-of-concept process achieves high yields under mild conditions and demonstrates a potential route for upcycling plastic waste into valuable pharmaceuticals.
17
Mar 2026
Researchers developed a scalable framework that predicts insulin resistance using wearable-device signals, routine blood biomarkers, and demographic data, with stronger performance when these data streams were combined. The study also introduced an AI agent to explain insulin resistance risk, interpret results, and support earlier metabolic risk screening.
17
Mar 2026
Researchers at The Hospital for Sick Children (SickKids) have uncovered how the bacteria that causes tuberculosis fuels itself during infection, providing new insights into one of the world's deadliest infectious diseases.